Politics, Policy & Law
Biopharma execs push back on Rep. Porter’s push to rein in M&A
Congressional report says biopharma acquisitions kill innovation, calls for FTC reviews, restraints.
A congressional report by California lawmaker Katie Porter says biopharma acquisitions kill innovation, calls for FTC reviews, restraints.
Rep. Katie Porter (D-Calif.), a rising voice in the progressive wing of the Democratic Party, has released a report that portrays biopharma mergers and acquisitions as harmful to innovation and recommends laws that would slow or restrict M&A.
The report fundamentally misrepresents the biopharma ecosystem, according to biopharma executives who spoke to